Pharmacological inhibition of ATR using M6620 represents a possible approach to decrease DNA repair and increase the sensitivity to cisplatin, and this is currently being studied in phase 1 trials for HNSCC (NCT02567422) [117,118]. This evidence concerns the gene ATR and head and neck squamous cell carcinoma.